Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07349498

Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation

This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hematopoietic Stem Cell Transplantation Cardiovascular Events Transplant Complication

Sex eligibility

All sexes

Study type

Observational

Primary location

Chinese PLA General Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.

Exclusion criteria

  • Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
  • Patient request to withdraw from the study.

Treatment and study plan

Primary outcomes

  1. Major adverse cardiovascular events (MACE)

    Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.

    Major adverse cardiovascular events (MACE) after hematopoietic stem cell transplantation.

Secondary outcomes

  1. Cardiovascular events

    Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.

    Cardiovascular events after hematopoietic stem cell transplantation, such as cardiovascular death, ischemic heart disease, coronary artery disease, stroke, heart failure, arrhythmia cardiomyopathy, myocarditis, endocarditis, valvular heart disease, and pericardial disease.

  2. Overall survival

    Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.

    Overall survival after hematopoietic stem cell transplantation.

  3. Event-free survival

    Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.

    Events were defined as the occurrence of any of the following after allo-HSCT: grade III-IV acute graft-versus-host disease (GVHD), chronic GVHD requiring systemic immunosuppression, relapse or progression of the hematologic disease, or death from any cause during follow-up.

  4. Complications of hematopoietic stem cell transplantation

    Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.

    Complications arising from hematopoietic stem cell transplantation range from early issues such as regimen toxicity and acute GVHD to late effects including chronic GVHD, organ dysfunction, and secondary malignancies.

Study contacts

Contact information is provided by the study sponsor or research team.

Xiao Hui Zhang

CONTACT

[email protected]

861088324577

Sponsors and collaborators

Lead sponsor

Peking University People's Hospital

Other

Collaborators

  • Chinese Academy of Medical Sciences
  • Chinese PLA General Hospital
  • First Affiliated Hospital Xi'an Jiaotong University
  • First Affiliated Hospital of Harbin Medical University
  • First Affiliated Hospital of Xinjiang Medical University
  • First Affiliated Hospital of Zhejiang University
  • Peking University First Hospital
  • Peking University Shenzhen Hospital
  • Peking University Third Hospital
  • Sichuan Provincial People's Hospital
  • Sun Yat-Sen University Cancer Center
  • The First Affiliated Hospital of Zhengzhou University
  • Tongji Hospital
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Xinqiao hospital of the third military medical university

Registry information

Official study title

Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT): A Prospective Multicenter Observational Study

Acronym: CORE-HCT

Important dates

Study start
2026
Primary completion
2036
Study completion
2036
First posted
Jan 16, 2026
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.